<DOC>
	<DOCNO>NCT02194465</DOCNO>
	<brief_summary>The main purpose study evaluate safety effectiveness study drug know LY2623091 participant high blood pressure .</brief_summary>
	<brief_title>A Study LY2623091 Participants With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Have history hypertension . If participant naïve treatment hypertension , treat antihypertensive medication within 30 day immediately prior screening : Have seat SBP ≥140 &lt; 170 millimeter mercury ( mmHg ) screen end leadin period . If participant currently treat hypertension : Are take stable dose 1 2 antihypertensive medication least previous 30 day . A combination antihypertensive medication 2 class consider 2 antihypertensive medication . Are willing discontinue antihypertensive medication study . Have seat SBP ≥140 &lt; 170 mmHg end leadin period . Have body mass index ( BMI ) ≥18.5 &lt; 40 kilograms/m^2 . Have history severe hypertension ( define SBP ≥180 mmHg and/or DBP ≥120 mmHg ) , secondary hypertension , symptomatic postural hypotension , hospitalization due hypertension . Have SBP ≥180 mmHg and/or DBP ≥110 mmHg screening , leadin period , randomization . Have history hospitalization due hyperkalemia , history drug discontinuation due elevate serum potassium level . Have serum potassium ≤3.5 &gt; 5.0 millimoles per liter ( mmol/L ) . Have estimate glomerular filtration rate ( eGFR ) &lt; 50 milliliters/minute/1.73 m^2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>